ArticleGeroScience2026
Characterization of the plasma proteomic profile of dual trajectories in cognitive status and physical performance.
Article in GeroScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Dual declines in cognitive status and physical performance increase dementia risk but shared biological mechanisms between processes remain unclear. We investigated plasma proteomic signatures underlying dual decline in older adults from the Invecchiare in Chianti cohort (n = 774; age ≥ 60). Group-based trajectory models with up to 15 years of data on cognitive status (global Mini-Mental State Examination scores) and 4-m gait speed identified three trajectories that included no decline, physical decline, or dual decline groups. At baseline, 1301 plasma proteins were measured with aptamer-based proteomics (SomaScan). Adjusted multinomial regressions identified proteins associated with group membership. Additional analyses included Reactome functional enrichment and partial least squares discriminant analysis (PLS-DA). Collectively, eight proteins were associated with differences across trajectory groups. Higher PI3, GDF15, TFF3, CCL15, TNNT2, and AGRP were associated with greater odds of dual decline, whereas higher CKM and GHR were linked to lower odds. PLS-DA confirmed and extended these findings. The top discriminators by variable-importance were PTN, TFF3, GDF15, IGFBP-2, and CHRDL1. Hierarchical clustering found PTN, IGFBP-2, PI3, GDF15, and TFF3 formed a coherent module. Functional enrichment highlighted overrepresentation of regulation of IGF transport and uptake by IGF binding proteins across decline trajectories and exploratory enrichment of post-translational protein phosphorylation and diseases of homeostasis. Older adults with dual declines showed a proteomic profile marked by cellular stress, inflammation, barrier injury, reduced IGF-1 bioavailability, and cardiovascular-metabolic strain. These findings support system-level hypotheses of dual decline and warrant replication, longitudinal proteomics, and evaluation of module-level markers.
Indexed as
Identifiers
42301613What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.